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Abstract
During open heart surgery the influence of a series of factors such as cardiopulmonary bypass (CPB), hypothermia,
operation and anaesthesia, as well as medication and transfusion can cause a diffuse trauma in the lungs. This
injury leads mostly to a postoperative interstitial pulmonary oedema and abnormal gas exchange. Substantial
improvements in all of the above mentioned factors may lead to a better lung function postoperatively. By avoid-
ing CPB, reducing its time, or by minimizing the extracorporeal surface area with the use of miniaturized circuits of
CPB, beneficial effects on lung function are reported. In addition, replacement of circuit surface with biocompatible
surfaces like heparin-coated, and material-independent sources of blood activation, a better postoperative lung
function is observed. Meticulous myocardial protection by using hypothermia and cardioplegia methods during
ischemia and reperfusion remain one of the cornerstones of postoperative lung function. The partial restoration of
pulmonary artery perfusion during CPB possibly contributes to prevent pulmonary ischemia and lung dysfunction.
Using medication such as corticosteroids and aprotinin, which protect the lungs during CPB, and leukocyte deple-
tion filters for operations expected to exceed 90 minutes in CPB-time appear to be protective against the toxic
impact of CPB in the lungs. The newer methods of ultrafiltration used to scavenge pro-inflammatory factors seem
to be protective for the lung function. In a similar way, reducing the use of cardiotomy suction device, as well as
the contact-time between free blood and pericardium, it is expected that the postoperative lung function will be
improved.
Introduction
Despite the improvement in the cardiopulmonary
bypass (CPB) techniques as well as the postoperative
intensive care, impaired pulmonary function is a well-
documented (by enormous experimental and clinical
evidence) complication of cardiopulmonary bypass,
resulting in increased morbidity and mortality [1-3].
However, whether CPB itself is directly responsible for
the whole postoperative lung dysfunction is still contro-
versial. It is indirectly suggested by some studies follow-
ing off-pump coronary artery bypass, which although an
attenuated inflammatory response has been shown, the
degree of postoperative lung dysfunction was similar
with that of conventional Coronary Artery Bypass Graft-
ing CABG [4,5]. Namely, for this postoperative pulmon-
ary dysfunction CPB may not be the only factor
contributing, but other factors related to the cardiac
operation such as anaesthesia, temporary cardiac dys-
function, infused catecholamines, altered mechanical of
thoracic cage, etc could play an important role [3,6-11].
The reported increased mortality and morbidity of this
early postoperative pulmonary dysfunction after cardiac
surgery may be related to the duration of mechanical
ventilation, neurological, renal and infectious complica-
tions, ICU and hospital stays, and subsequently
increased mortality [12]. Despite the well-documented
impairment of pulmonary function even after uncompli-
cated CPB, effective precautions and ideal management
strategies for this problem are still under debate [3,4].
The scope of this review is, therefore, to highlight the
path of genetic and pathophysiological mechanisms
involved in this injury, and the possible perioperative
therapeutic options and manipulations that could be
implemented, in order to alleviate the expected post-
operative lung dysfunction. * Correspondence: ngbaik@yahoo.com
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1. Prevention and management of the inflammatory
reaction due to CPB
Since the inflammatory response of CPB is multifactorial,
a combined therapeutic approach should be implemented
for the attenuation of the clinical sequelae. On the one
hand, the abrogation of CPB by using Off-Pump techni-
ques alone is not possible in many cases, and on the other
hand, this technique alone does not seem to fully alleviate
postoperative lung dysfunction [13,14]. Other modifica-
tions of CPB techniques, such as the utilization of
heparin-coated circuits, use of ultra-filtration techniques
or the use of the Drew-Anderson technique, may be bene-
ficial for a reduction in the observed activation of systemic
inflammatory response syndrome (SIRS) or the scavenging
of various pro-inflammatory cytokines [4,15,16].
1.1 Inversion to Off-Pump operations
Although CPB causes disturbances in lung mechanics, it
may not be on its own a major contributor to the
observed postoperative gas exchange abnormalities fol-
lowing heart operations [3,17,18]. To date the experi-
mental and clinical data comparing On-pump and Off-
pump surgery suggest an affected cardiac function in
favour of Off-Pump operations, expressed by a reduced
tissue oxygenation, a phenomenon which might be
related to a greater myocardial damage during hypother-
mic CPB operations [14,19-21]. In addition, the higher
lactate levels in the CPB group suggest greater tissue O2
demands after hypothermic CPB perfusion in compari-
son with those demands with Off-pump surgery [22].
Although initial studies showed reduction in indexes of
systemic inflammation after OPCAB and pulmonary
complications [23], the negative influence of CPB on the
lungs, is not apparent by comparing conventional CABG
with Off-Pump Coronary Artery Bypass (OPCAB).
Indeed, some clinical studies showed that, both On-
pump and Off-pump CABG patients experienced similar
degrees of decreased PaO2 and increased P(A-a)O2,b u t
a higher percentage of pulmonary shunt fraction after
On-pump operations [17,18,24]. However, a randomized
study by Staton et al [25] compared the postoperative
lung function after OPCAB and conventional CABG,
concerning fluid balance, hemodynamics, arterial blood
gases, chest radiographs, spirometry, pulmonary compli-
cations, and extubation-time. Paradoxically, postopera-
tive compliance was reduced more after OPCAB, and
fluid balance was significantly higher in the same group.
Despite these changes, immediate postoperative PaO2
on FiO2 of 1.0 was significantly higher after OPCAB and
extubation-time was significantly shorter, while the
postop-chest radiographs, spirometry, mortality, re-intu-
bation, or re-admission for pulmonary complications,
were not significantly different between groups [25]. In
conclusion, although it is impossible to perform all the
heart operations without CPB, this hypothetical inver-
sion alone cannot prevent systemic inflammatory reac-
tion and lung function impairment. Although this
scenario can abolish the negative effects of CPB on lung
function it is not able to diminish completely the pro-
inflammatory factors that are produced, despite the fact
that the postoperative lung impairment seems to be
generated to a lesser extent.
1.2 Heparin-coated circuits and new-technology circuits
The hostile surface of extracorporeal circuit is consid-
ered to be a major factor of inflammatory reaction.
Over the last years a large improvement has been
observed in the construction and the clinical use of cir-
cuits lined with more biocompatible coating. The fol-
lowing have been used as coating materials: heparin
[4,15,16], poly-2-methoxyethyl acrylate [26], synthetic
protein [27], and phosphorylcholine [28]. The first and
most extensively studied coating material used is that of
heparin. The concept behind heparin coating is to
mimic the endothelial surface that contains heparin sul-
phate [2]. Hence, the main beneficial effects of heparin-
coated circuits are considered to be the following two:
first, a reduction of complement activation (and mainly
of factor C5a) ranging between 25% and 45% [29,30],
and second, a reduction of the inflammatory reaction
which is thought to be accomplished in two ways:
through a reduction of complement activation, and
through binding of phospholipase A2 [31]. Heparin
reduces the inflammatory responses especially as far as
the actions of platelets, leukocytes, and endothelial cells
are concerned [31-34]. This effect is noticeable by a
decreased production of IL-6, IL-8, E-selectin, lactoferin,
myeloperoxidase, integrin, selectin, and platelet b-
thromboglobulin release, and reduced production of
oxygen free radicals, as well [31-34]. Concisely, all the
above described effects of heparin-coated circuits should
have beneficial impact on clinical outcomes. Indeed, a
clinical study showed a decreased intrapulmonary shunt
with improved respiratory index (PO2/FiO2)a f t e rC P B
by using heparin-coated circuits, although intubation
time and ICU stay were not affected [35]. Others, using
a scoring-system based either on intubation time, the
central-peripheral temperature difference, the postopera-
tive fluid balance, and on various adverse effects after
CABG, showed a significantly positive clinical effect in
patients treated with heparin-coated circuits, and espe-
cially in patients with cross-clamp times exceeding 60
min [16,36]. De Vroege et al [31] demonstrated com-
paratively significant postoperative differences in favour
of the patients treated with heparin-coated circuits in
terms of the pulmonary shunt fraction, the pulmonary
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well as various inflammatory markers reflecting comple-
mentary activation. In addition, they found reduced acti-
vation of pulmonary capillary endothelial cells in the
same group of patients, suggesting that the heparin-
coated circuit may have beneficial effects on pulmonary
function [31]. Compared with conventional circuits, the
heparin-coated may improve lung compliance and pul-
monary vascular resistance and thus reduce intrapul-
monary-shunt [37]. However, most clinical studies have
shown, that these beneficial effects did not influence the
intubation-time or the ICU-stay of patients [31,37,38].
Furthermore, in contrast to initial expectations, throm-
bin generation and the activity of the fibrinolytic system
were not reduced using heparin-coated circuits [39].
Recently, Speekenbrink et al [40], proposed a novel min-
iaturized CPB system with the aim to attenuate lung and
other organ dysfunction, and generally to diminish the
inflammatory reaction and the derangement of patient
homeostasis. The principles of this system described
also by others [40-43] are the following: it uses a low
prime volume of only 800 versus 2000 ml for the con-
ventional system; all of circuit components are heparin-
coated and primed with aprotinin; it is a closed-volume
system;, it uses an additional pump for the venous line;,
and in addition, it uses a “controlled-suction’ system, or
a “cell-saving” system, to minimize the contact-time
between blood and non-endothelialized tissues. A large
amount of the priming volume can be extracted from
the extracorporeal circuit by “controlled exsanguina-
tions” of the patient into the circuit, and as a result the
unpleasant hemodilution may be reduced [40]. By using
his system, the reduction in complementary activation is
reduced by 25 to 45% and as a result, the expected
impairment on lung function is reduced [40]. Nollert at
al [44] compared the outcomes with conventional CPB
and miniaturized cardiopulmonary bypass after CABG
in 30 patients, concerning the inflammation and coagu-
lation, measuring levels of IL-2, IL-6, IL-10, TNF, CRP,
WBC differentiation, d-dimers, fibrinogen, and platelet’s
number. Surprisingly, they did not find any significant
difference of any parameter of inflammation or clinical
outcomes (blood loss, need for blood products, ICU-stay
and hospital-stay) amongst the two groups. However, in
two cases dangerous air leaks occurred in the closed
miniaturized circuit, suggestive of a more narrow safety
margin. Therefore, the expected protective effect on
lung function by using these systems seems to be insuf-
ficient for broad clinical use at the time this review is
written.
1.3 Leukocyte depletion
Since experimental studies have documented that leuko-
cytes were entrapped into the capillaries of lungs [45]
and play an important role in the inflammatory reaction
after CPB, their depletion during CPB, may be benefi-
cial. Indeed, experimental studies showed that leukocyte
depletion by filtration reduced heart and lung reperfu-
sion injury [45]. However, clinical comparative studies
have shown ambiguous results. Some of them showed
better preserved lung function and reduced free oxygen
radicals production following CPB, expressed by
improved PaO2 [45-47] while others did not show any
difference [48,49] despite the reduced IL-8 production
[48]. Other studies have shown, that, although the leu-
kocyte depletion filter of the arterial line removes leuko-
cytes from the circulation, the systemic neutrophil
count may [49,50] or may not be reduced [51]. A rando-
mized study compared the effectiveness of leukocyte fil-
ter depletion with a common arterial filter, in patients
undergoing conventional CABG. They found signifi-
cantly better oxygenation indices; lower extravascular
lung water scores, and less duration of postoperative
mechanical ventilation in the leukocyte depletion filter
group [52]. In addition, leukocyte filtration did not offer
any significant preservation of lung function, for CPB-
time less than 90 minutes. Warren et al [53], in their
extensive review examined the effectiveness of several
leukocyte depletion filters, used in cardiac surgery. They
concluded that: a) whilst the filters did not appear to
significantly lower leukocyte count, they may preferen-
tially remove activated leukocytes, b) a small improve-
ment in lung function is evident early postoperatively,
but this does not lead to decrease mortality or better
clinical outcomes, c) their use attenuates the reperfusion
injury at the cellular level, but without substantial clini-
cal improvement, and d) up to date there are no evi-
dence-based data to support the routine use in cardiac
surgery.
1.4 Ultrafiltration
Ultrafiltration was used in cardiac surgery for removing
volume of priming and reducing the postoperative
oedema, the total body water, but specifically that of
lungs resulting in better oxygenation postoperatively
[54,55]. Besides this function, it has been postulated that
ultrafiltration may remove also destructive and inflam-
matory substances from the circulation, inflammatory
cytokines, and scavenge toxins [56]. Indeed, various stu-
dies have shown that by using ultrafiltration the levels
of IL-6, IL-8, as well as systemic oedema formation, or
pulmonary hypertension can be effectively reduced,
while concomitant improvement of the lung function
(reduced alveolar-capillary oxygen pressure gradient) is
recorded [56-58]. Another comparative study in children
showed, that the conventional ultrafiltration resulted in
a significant immediate improvement in static lung com-
pliance and dynamic lung compliance, as well as gas
exchange capacity. However, this effect is observed only
for the first 6 postoperative hours and did not result in
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tion-time, ICU-stay, or hospital-stay) [57]. A similar
comparative study
54 showed that: a) the pulmonary
function was improved via a significantly increased pul-
monary compliance, a decreased airway resistance and
an improved pulmonary gas exchange after CPB, as
reflected by a decreased alveolo-arterial oxygen gradient,
b) the levels of serum IL-6 in the modified ultrafiltration
group were much lower than in the control group, c)
the thromboxane B2 was significantly removed by ultra-
filtration contributing to a lower lung vessels permeabil-
ity, and, finally, d) ultrafiltration did not affect the levels
and the action of endothelin-1. Finally, the main advan-
tage of ultrafiltration seems to be, in our opinion, the
desirable increase of colloid oncotic pressure which sub-
sequently prevents the development of pulmonary inter-
stitial oedema.
1.5 Hemodilution
The mixing of the priming solution with the patient’s
own blood at the beginning of CPB results in an abrupt
hemodilution [48]. This hemodilution is desirable, since
it facilitates the tissue-perfusion. However, if the hema-
tocrit is restored below a level of 23%, it has been
shown to contribute to an increased interstitial oedema
in vital organs (e.g., brain, lungs, myocardium), resulting
in increased mortality [59]. Consequently, by increasing
the colloid oncotic pressure of the priming solution
(replacement of crystalloids with colloids), Jansen et al
showed that the postoperative course was improved and
the hospital-stay significantly reduced [60]. Another
study showed that better hemodynamic parameters such
as arterial pressure, cardiac index, and vascular resis-
tance, and higher oxygen delivery can be achieved by
the reduction of priming volumes [61].
Similarly, other methods used to prevent excessive
hemodilution during extracorporeal circulation, such as
the use of blood cardioplegia or perioperative hemofil-
tration, showed even further reduction of blood transfu-
sions [40].
In conclusion, clinical data suggests that the most
important result of “controlled hemodilution” contribute
to a reduced interstitial lung oedema and therefore to
an improvement of postoperative lung function.
1.6 The cardiotomy suction
Various studies have shown that the collected pericar-
dial blood during the cardiac operations using CPB, is
activated by tissue plasminogen activator (t-PA), while it
has been additionally found to contains pro-coagulants
and platelets factors [40,62]. However, this does not
mean that this specific blood is partially activated or
that it contains fibrinogen degradation products, and,
that its re-transfusion may interact with platelets to
form undesirable complexes, and derangements of hae-
mostasis [40]. Indeed, various clinical studies have
confirmed that the re-transfusion of blood collected in
the pericardium during CPB induces a dose-dependent
inflammatory response, impairs hemostasis, enhance
various inflammatory reactions, and also impair the
postoperative lung function [63,64]. In order to reduce
this cascade of activation of pericardial blood, various
techniques have been propose d .F i r s t ,ar e d u c t i o no f
time between the contact of shed blood with the peri-
cardium and its re-transfusion might diminish the
induced inflammatory reaction [40,65]. Second, the use
of a controlled suction device which incorporates a level
sensor that is activated only when blood accumulates in
the pericardium, minimizes air entering into the suction
line, and thus the formation of activating air-blood
interfaces [40]. Third, the topical administration of apro-
tinin into the surgical wound and the pericardium has
been shown to inhibit the hyper-fibrinolysis that occurs
in the pericardial blood which in turn leads to improved
hemostasis [66]. Finally, since heparin levels in the re-
aspirated pericardial blood have been shown to be lower
than systemic levels, topical administration of heparin
might also reduce the activation of pericardial blood, by
reducing thrombin activity [67].
1.7 Pharmacological manipulations
Corticosteroids
An experimental study showed that after pre-treatment
with methylprednisolone the postoperative lung func-
tion, expressed by alveolar-arterial oxygen gradient, pul-
monary vascular resistance, and extracellular lung water,
was improved [68]. In a similar way, clinical studies
have shown that administration of corticosteroids before
CPB inhibits the production of pro-inflammatory cyto-
kines IL-6, IL-8, and TNFa, while it simultaneously
increases the IL-10 levels, which exerts an anti-inflam-
matory action [16,69]. Other studies showed that
methylprednisolone administration can inhibit neutro-
phil CD11b expression and neutrophil complement-
induced chemotaxis, thereby decreasing neutrophil acti-
vation and post-CPB neutropenia [4,70-72]. In contrast,
other clinical studies did not obtain to confirm the
superiority of methyl-prednisolone administration dur-
ing cardiac surgery concerning the postoperative alveo-
lar-arterial oxygen gradient, the pulmonary shunt, the
lung compliance or the intubation-time [73,74]. How-
ever, although evidence-based guidelines are still lacking,
some authors remain adherents of steroid administra-
tion and consider it as a “fundamental strategy” in their
fast-track recovery protocol [4,15,72].
Aprotinin
Hill et al in a clinical study described that the adminis-
tration of aprotinin in patients following CPB reduced
the levels of TNF-a, neutrophil elastase release, comple-
mentary activation, neutrophil CD11 upregulation, as
well as lower IL-8 levels in the bronchoalveolar lavage
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[71,75]. Others reported that these effects of aprotinin
on the inflammatory response to CPB were dose depen-
dent [76]. Specimens from the lung of patients receiving
aprotinin before CPB contained reduced levels of of
malondialdehyde, a marker of oxygen free radical
damage, higher glutathione peroxidase levels, and
reduced leukocyte sequestration [77]. The addition of
aprotinin in the priming solution in recipients under-
going heart transplantation showed, that the inflamma-
tory response, and in particular the postoperative
pulmonary dysfunction, were both attenuated, resulting
in a reduced postoperative morbidity and ICU-stay [78].
Heparin
Heparin is nowadays still considered as absolutely neces-
sary for open heart operations. On the other hand, stu-
dies have shown that heparin administration a), results
in a rapid release of t-PA from its body sources, which
may induce fibrinolysis [79], b) causes (in vitro) inhibi-
tion of platelet function in more than 30% of patients,
thus leading to increased postoperative blood loss [80],
c) has pro-activating properties on granulocytes and pla-
telets [81], and finally d), heparin after its neutralization
with protamine, is inducing an activation of the comple-
ment system, action which is correlated with postopera-
tive pulmonary shunt fraction [82]. To avoid these
adverse effects of heparin, some possible alternatives
have been proposed. The recombinant form of platelet-
factor 4, which binds and subsequently inhibits heparin,
could be used as an attractive alternative to protamine
[83]. Recombinant hirudin, a selective thrombin inhibi-
tor derived from leeches, is another possible attractive
alternative [40], which has shown in experiments good
clinical results without increased bleeding tendency
[40,84]. However, disadvantages from the use of recom-
binant hirudin are the absence of specific antidote, the
possible activation and depletion of other factors of the
coagulation cascade, as well as it does not completely
inhibit the formation of thrombin [40]. Therefore,
heparin still remains irreplaceable but possibly in the
near future there might be a role for hirudin as an
adjunct to heparin.
Monoclonal anticytokine antibodies
To date some authors believe, that in the near future
the perioperative administration of monoclonal anticyto-
kine antibodies which reduce the levels of pro-inflam-
matory cytokines during open heart operations, might
attenuate the harmful influence of CPB on the lungs
[5,15,40].
1.8 Continuing ventilation during CPB
Apnoea during CPB has been suggested to promote
activation of lysosomal enzymes in the pulmonary circu-
lation, which in turn are correlated with the incidence
of postoperative pulmonary dysfunction (ALI or ARDS)
[85]. To prevent this dysfunction, it has been applied
some maneuvers such as the intermittent ventilation or
application of continuous airway pressure (CPAP) dur-
ing CPB [5,40,86]. CPAP application during CPB has
been reported as an effective adjunct in some studies
[86,87]. However, others reported either no difference,
or a non-significant difference lasting less than 4 to 8
hours between patients treated with CPAP compared to
controls [9,88,89]. Maintaining ventilation together with
pulmonary artery perfusion during CPB has been pro-
posed as another option to attenuate the post-CPB
impairment of lung function. Indeed, Friedman et al
[90] in an experimental comparative study showed that
ventilation with pulmonary artery perfusion during CPB
should have a beneficial role in preserving lung function,
possibly by reducing platelet and neutrophil sequestra-
tion and attenuating the TXB2 response after CPB. In
contrast to this, another experimental study showed that
continuous ventilation during CPB provided no signifi-
cant improvement in pulmonary vascular resistance,
respiratory index, or oxygen tensions [91]. More
r e c e n t l y ,J o h ne ta l[ 9 2 ]s h o w e di nt h e i rr a n d o m i z e d
study that continued ventilation during CPB by tidal
volume of 5 ml/Kg resulted significant smaller extravas-
cular lung water and a shorter extubation-time. To date,
the evidence for clear benefits of maintaining ventilation
alone during CPB is inconsistent, with most studies
showing no significant preservation of lung function
[5,88]. Similarly, no differences in pulmonary membrane
permeability were found between ventilated and non-
ventilated patients undergoing CPB [93].
2. Prevention and management of other (except of
cardiopulmonary bypass) causes of lung dysfunction
Indirect factors of lung dysfunction are the ischemia and
reperfusion of the heart, which have been linked with
increased production some pro-inflammatory factors
[29,94,95]. Myocardial cooling and cardioplegia perfu-
sion have been shown to attenuate the negative effects
of ischemia on the heart after cross-clamping of the
aorta, by reducing the metabolic demand of the myocar-
dium [40]. Nevertheless, ischemia will occur or is
already present owing to the disease process that is
being treated. The ischemia will consume high-energy
phosphate of cells and may cause a degree of reversible
or irreversible myocardial damage [40]. Proposed media-
tors of reperfusion injury following ischemia involve the
generation of oxygen free radicals produced via the
xanthine oxidase reaction. Exposure of the ischemic
endothelium to these radicals induces a rapid up-regula-
tion of P-selectin and integrin expression [96]. At the
beginning of reperfusion this will result in the accumu-
lation of more activated neutrophils, which shed their
cytotoxic enzymes, cytokines, and oxygen free radicals
on the endothelium, leading finally to an extensive tissue
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tion of nitric oxide (NO) synthase will reduce NO pro-
duction which may produce coronary spasm and the
no-reflow phenomenon [97,98]. Possible ways to reduce
reperfusion injury include maintenance of physiological
oxygen concentration during CPB, oxygen radical sca-
vengers administration, inhibition of xanthine oxidase
by allopurinol, as well as drastic reduction of ischemia
by using continuous warm blood cardioplegia techni-
ques [99-102].
Conclusions
It is clear that many factors are involved in the detri-
mental effects of CPB in all organs and especially in the
lungs [3]. Therefore, substantial improvements in the
process of CPB can only be obtained when a multi-fac-
torial approach is followed, directed at both material-
dependent and material-independent factors [40]. There
is a huge research to this direction and most of the
results are still debatable. However, we could herein
summarize the most important beneficial manipulations.
a) By abolition of CPB or by reducing as much as
possible its time, a better postoperative lung function
is expected [103,104].
b) By minimizing the extracorporeal-circuit surface
area (miniaturized-circuits), the endothelial injury,
the granulocytes sequestration and its activation is
expected to be much lower [105,106].
c) By replacement of circuit-surfaces with “biocom-
patible” surfaces as these of heparin-coated, and
material-independent sources of blood activation,
the expected post-CPB lung injury should be lower
[31,40].
d) By maintaining pulmonary artery perfusion during
CPB, the lung ischemia is prevented [15,90,107,108].
e) By using “lung-protective” medication such as
corticosteroids and aprotinin, the lungs should be
protected against the toxic influence of CPB
[4,72,77,102].
f) By using selectively the Drew-Anderson technique
to abrogate the xenograft oxygenator, the reduced
granulocyte sequestration in the lungs and the mini-
mal complement activation preserve a better post-
operative lung function [109,110] the font was
corrected here
g) By using (conventional or modified) ultrafiltration
during CPB, some pro-inflammatory factors espe-
cially “toxic” for the lung function are scavenged
[54-56].
h) By drastic reduction of cardiotomy suction to the
minimum or by using a controlled cardiotomy suc-
tion system which minimizes superfluous suctioning
and air entering the pericardial suction line, the
postoperative lung function is significantly preserved
[48,62-65].
i) By using leukocyte depletion filters for expected
long-lasting CPB-time (>90 minutes), a reduced free
oxygen radicals production and a better preserved
lung function can be achieved [5,52,53].
j) By meticulous application of rules of myocardial
protection (during ischemia and reperfusion) the
lungs are indirectly protected from several pro-
inflammatory factors produced during this process
[96,101].
Author details
1Department of Cardiothoracic Surgery, University of Patras, School of
Medicine, Patras, Greece.
2Department of Cardiac Surgery, University of
Ioannina, School of Medicine, Ioannina, Greece.
3Department of Clinical
Anaesthesiology and Intensive Postoperative Care Unit, University of
Ioannina, School of Medicine, Ioannina, Greece.
Authors’ contributions
All authors: 1. have made substantial contributions to conception and
design, or acquisition of data, or analysis and interpretation of data; 2. have
been involved in drafting the manuscript or revisiting it critically for
important intellectual content; 3. have given final approval of the version to
be published.
Competing interests
The authors declare that they have no competing interests.
Received: 24 September 2009
Accepted: 11 January 2010 Published: 11 January 2010
References
1. Menasche P, Edmunds LHJ: The inflammatory response, Cardiac Surgery
in the Adult. McGraw HillCohn LH, Edmunds LH , 2 2003, 349-60.
2. Altmay E, Karaca P, Yurtseven N, Ozkul V, Aksoy T, Ozler A, Canik S:
Continuous positive airway pressure does not improve lung function
after cardiac surgery. Can J Anaesth 2006, 53:919-25.
3. Apostolakis E, Filos K, Koletsis E, Dougenis D: Lung Dysfunction Following
Cardiopulmonary Bypass. J Card Surg 2009.
4. Hall RI, Smith MS, Rocker G: The systemic inflammatory response to
cardiopulmonary bypass: pathophysiological, therapeutic, and
pharmacological considerations. Anesth Analg 1997, 85:766-82.
5. Ng CS, Wan S, Yim AP, Arifi AA: Pulmonary dysfunction after cardiac
surgery. Chest 2002, 121:1269-77.
6. Taggart DP, el Fiky M, Carter R, Bowman A, Wheatley DJ: Respiratory
dysfunction after uncomplicated cardiopulmonary bypass. Ann Thorac
Surg 1993, 56:1123-8.
7. Vargas FS, Cukier A, Terra-Filho M, Hueb W, Teixeira LR, Light RW:
Relationship between pleural changes after myocardial revascularization
and pulmonary mechanics. Chest 1992, 102:1333-6.
8. Hill GE, Whitten CW, Landers DF: The influence of cardiopulmonary
bypass on cytokines and cell-cell communication. J Cardiothorac Vasc
Anesth 1997, 11:367-75.
9. Magnusson L, Zemgulis V, Wicky S, Tyden H, Hedenstierna G: Effect of
CPAP during cardiopulmonary bypass on postoperative lung function.
An experimental study Acta Anaesthesiol Scand 1998, 42:1133-8.
10. Boldt J, King D, Scheld HH, Hempelmann G: Lung management during
cardiopulmonary bypass: influence on extravascular lung water. J
Cardiothorac Anesth 1990, 4:73-9.
11. Chai PJ, Williamson JA, Lodge AJ, Daggett CW, Scarborough JE,
Meliones JN, Cheifetz IM, Jaggers JJ, Ungerleider RM: Effects of ischemia
on pulmonary dysfunction after cardiopulmonary bypass. Ann Thorac
Surg 1999, 67:731-5.
Apostolakis et al. Journal of Cardiothoracic Surgery 2010, 5:1
http://www.cardiothoracicsurgery.org/content/5/1/1
Page 6 of 912. Rady MY, Ryan T, Starr NJ: Early onset of acute pulmonary dysfunction
after cardiovascular surgery: risk factors and clinical outcome. Crit Care
Med 1997, 25:1831-9.
13. Tschernko EM, Bambazek A, Wisser W, Partik B, Jantsch U, Kubin K,
Ehrlich M, Klimscha W, Grimm M, Keznickl FP: Intrapulmonary shunt after
cardiopulmonary bypass: the use of vital capacity maneuvers versus off-
pump coronary artery bypass grafting. J Thorac Cardiovasc Surg 2002,
124:732-8.
14. Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, Marshall JJ,
Leimbach M, Huber P, Garas S, Sammons BH, McCall SA, Petersen RJ,
Bailey DE, Chu H, Mahoney EM, Weintraub WS, Guyton RA: Off-pump
coronary artery bypass grafting provides complete revascularization
with reduced myocardial injury, transfusion requirements, and length of
stay: a prospective randomized comparison of two hundred unselected
patients undergoing off-pump versus conventional coronary artery
bypass grafting. J Thorac Cardiovasc Surg 2003, 125:797-808.
15. Richter JA, Meisner H, Tassani P, Barankay A, Dietrich W, Braun SL: Drew-
Anderson technique attenuates systemic inflammatory response
syndrome and improves respiratory function after coronary artery
bypass grafting. Ann Thorac Surg 2000, 69:77-83.
16. Jansen PG, te VH, Huybregts RA, Paulus R, Bulder ER, Spoel van der HI,
Bezemer PD, Slaats EH, Eijsman L, Wildevuur CR: Reduced complement
activation and improved postoperative performance after
cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc
Surg 1995, 110:829-34.
17. Cox CM, Ascione R, Cohen AM: Effect of cardiopulmonary bypass on
pulmonary gas exchange: a prospective randomised study. Ann Thorac
Surg 2000, 69:140-5.
18. Kochamba GS, Yun KL, Pfeffer TA, Sintek CF, Khonsari S: Pulmonary
abnormalities after coronary arterial bypass grafting operation:
cardiopulmonary bypass versus mechanical stabilization. Ann Thorac Surg
2000, 69:1466-70.
19. Van Dijk D, Nierich AP, Jansen EWL, Nathoe HM, Suyker WJL, Diephuis JC,
Van Boven WJ, Borst C, Buskens E, Grobbee DE, Robles de Medina EO, De
Jaegere PPT: Early outcome after off-pump versus on-pump coronary
bypass surgery: results from a randomized study. Circulation 2001,
104:1761-6.
20. Khan NE, De Souza A, Mister R, Flather M, Clague J, Davies S, Collins P,
Wang D, Sigwart U, Pepper J: A randomized comparison of off-pump and
on-pump multivessel coronary artery bypass surgery. N Engl J Med 2004,
350:21-8.
21. Kobayashi J, Tashiro T, Ochi M, Yaku H, Watanabe G, Satoh T, Tagusari O,
Nakajima H, Kitamura S: Early outcome of a randomized comparison of
off-pump and on-pump multiple arterial coronary revascularization.
Circulation 2005, 112:I338-I343.
22. Groeneveld AJ, Jansen EK, Verheij J: Mechanisms of pulmonary
dysfunction after on-pump and off-pump cardiac surgery: a prospective
cohort study. J Cardiothorac Surg 2007, 2(11):11.
23. Yokoyama T, Baumgartner FJ, Gheissari A, Capouya ER, Panagiotides GP,
Declusin RJ: Off-pump versus on-pump coronary bypass in high-risk
subgroups. Ann Thorac Surg 2000, 70:1546-50.
24. Taggart DP: Respiratory dysfunction after cardiac surgery: effects of
avoiding cardiopulmonary bypass and the use of bilateral internal
mammary arteries. Eur J Cardiothorac Surg 2000, 18:31-7.
25. Staton GW, Williams WH, Mahoney EM, Hu J, Chu H, Duke PG, Puskas JD:
Pulmonary outcomes of off-pump vs on-pump coronary artery bypass
surgery in a randomized trial. Chest 2005, 127:892-901.
26. Suhara H, Sawa Y, Nishimura M, Oshiyama H, Yokoyama K, Saito N,
Matsuda H: Efficacy of a new coating material, PMEA, for
cardiopulmonary bypass circuits in a porcine model. Ann Thorac Surg
2001, 71:1603-8.
27. Wimmer-Greinecker G, Matheis G, Martens S, Oremek G, Abdel-Rahman U,
Moritz A: Synthetic protein treated versus heparin coated
cardiopulmonary bypass surfaces: similar clinical results and minor
biochemical differences. Eur J Cardiothorac Surg 1999, 16:211-7.
28. De Somer F, Francois K, van Oeveren W, Poelaert J, De Wolf D, Ebels T, Van
Nooten G: Phosphorylcholine coating of extracorporeal circuits provides
natural protection against blood activation by the material surface. Eur J
Cardiothorac Surg 2000, 18:602-6.
29. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE: Reduced
complement activation with heparin-coated oxygenator and tubings in
coronary bypass operations. J Thorac Cardiovasc Surg 1992, 103:806-13.
30. Ovrum E, Mollnes TE, Fosse E, Holen EA, Tangen G, Abdelnoor M,
Ringdal MA, Oystese R, Venge P: Complement and granulocyte activation
in two different types of heparinized extracorporeal circuits. J Thorac
Cardiovasc Surg 1995, 110:1623-32.
31. de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA,
Hack CE, van Barneveld L, Eijsman L, Wildevuur CR: The impact of heparin-
coated cardiopulmonary bypass circuits on pulmonary function and the
release of inflammatory mediators. Anesth Analg 2004, 98:1586-94.
32. Weerwind PW, Maessen JG, van Tits LJ, Stad RK, Fransen EJ, de Jong DS,
Penn OC: Influence of Duraflo II heparin-treated extracorporeal circuits
on the systemic inflammatory response in patients having coronary
bypass. J Thorac Cardiovasc Surg 1995, 110:1633-41.
33. Bozdayi M, Borowiec J, Nilsson L, Venge P, Thelin S, Hansson HE: Effects of
heparin coating of cardiopulmonary bypass circuits on in vitro oxygen
free radical production during coronary bypass surgery. Artif Organs
1996, 20:1008-16.
34. Fukutomi M, Kobayashi S, Niwaya K, Hamada Y, Kitamura S: Changes in
platelet, granulocyte, and complement activation during
cardiopulmonary bypass using heparin-coated equipment. Artif Organs
1996, 20:767-76.
35. Ranucci M, Cirri S, Conti D, Ditta A, Boncilli A, Frigiola A, Menicanti L:
Beneficial effects of Duraflo II heparin-coated circuits on postperfusion
lung dysfunction. Ann Thorac Surg 1996, 61:76-81.
36. Wildevuur CR, Jansen PG, Bezemer PD, Kuik DJ, Eijsman L, Bruins P, De
Jong AP, Van Hardevelt FW, Biervliet JD, Hasenkam JM, Kure HH, Knudsen L,
Bellaiche L, Ahlburg P, Loisance DY, Baufreton C, Le Besnerais P, Bajan G,
Matta A, Van Dyck M, Renotte MT, Ponlot-Lois A, Baele P, McGovern EA,
Ahlvin E: Clinical evaluation of Duraflo II heparin treated extracorporeal
circulation circuits (2nd version). The European Working Group on
heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg
1997, 11:616-23.
37. Wan S, LeClerc JL, Antoine M, DeSmet JM, Yim AP, Vincent JL: Heparin-
coated circuits reduce myocardial injury in heart or heart-lung
transplantation: a prospective, randomized study. Ann Thorac Surg 1999,
68:1230-5.
38. te Velthuis H, Baufreton C, Jansen PG, Thijs CM, Hack CE, Sturk A,
Wildevuur CR, Loisance DY: Heparin coating of extracorporeal circuits
inhibits contact activation during cardiac operations. J Thorac Cardiovasc
Surg 1997, 114:117-22.
39. Gorman RC, Ziats N, Rao AK, Gikakis N, Sun L, Khan MM, Stenach N,
Sapatnekar S, Chouhan V, Gorman JH III, Niewiarowski S, Colman RW,
Anderson JM, Edmunds LH Jr: Surface-bound heparin fails to reduce
thrombin formation during clinical cardiopulmonary bypass. J Thorac
Cardiovasc Surg 1996, 111:1-11.
40. Speekenbrink R, van Oeveren W, Wildevuur C: Pathophysiology of
cardiopulmonary bypass, Minimally Invasive Cardiac Surgery. Totowa
New Jersey Humana PressGolstein D, Oz M , 2 2004, 3-18.
41. Jegger D, Tevaearai HT, Horisberger J, Mueller XM, Boone Y, Pierrel N,
Seigneul I, von Segesser LK: Augmented venous return for minimally
invasive open heart surgery with selective caval cannulation. Eur J
Cardiothorac Surg 1999, 16:312-6.
42. Nakanishi K, Shichijo T, Shinkawa Y, Takeuchi S, Nakai M, Kato G, Oba O:
Usefulness of vacuum-assisted cardiopulmonary bypass circuit for
pediatric open-heart surgery in reducing homologous blood transfusion.
Eur J Cardiothorac Surg 2001, 20:233-8.
43. Rosengart TK, DeBois W, O’Hara M, Helm R, Gomez M, Lang SJ, Altorki N,
Ko W, Hartman GS, Isom OW, Krieger KH: Retrograde autologous priming
for cardiopulmonary bypass: a safe and effective means of decreasing
hemodilution and transfusion requirements. J Thorac Cardiovasc Surg
1998, 115:426-38.
44. Nollert G, Schwabenland I, Maktav D, Kur F, Christ F, Fraunberger P,
Reichart B, Vicol C: Miniaturized cardiopulmonary bypass in coronary
artery bypass surgery: marginal impact on inflammation and
coagulation but loss of safety margins. Ann Thorac Surg 2005, 80:2326-32.
45. Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM,
Reitz BA, Baumgartner WA: Leukocyte depletion ameliorates free radical-
mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc
Surg 1990, 99:873-7.
Apostolakis et al. Journal of Cardiothoracic Surgery 2010, 5:1
http://www.cardiothoracicsurgery.org/content/5/1/1
Page 7 of 946. Morioka K, Muraoka R, Chiba Y, Ihaya A, Kimura T, Noguti H, Uesaka T:
Leukocyte and platelet depletion with a blood cell separator: effects on
lung injury after cardiac surgery with cardiopulmonary bypass. J Thorac
Cardiovasc Surg 1996, 111:45-54.
47. Sheppard SV: Mechanisms and technical aspects of leucocyte depletion,
Leukocyte Depletion in Cardiac Surgery and Cardiology. Karger Matheis
G, Moritz A, Scholz M 2002, 16-32.
48. Gu YJ, de Vries AJ, Vos P, Boonstra PW, van Oeveren W: Leukocyte
depletion during cardiac operation: a new approach through the
venous bypass circuit. Ann Thorac Surg 1999, 67:604-9.
49. Mihaljevic T, Tonz M, von Segesser LK, Pasic M, Grob P, Fehr J, Seifert B,
Turina M: The influence of leukocyte filtration during cardiopulmonary
bypass on postoperative lung function. A clinical study. J Thorac
Cardiovasc Surg 1995, 109:1138-45.
50. Johnson D, Thomson D, Mycyk T, Burbridge B, Mayers I: Depletion of
neutrophils by filter during aortocoronary bypass surgery transiently
improves postoperative cardiorespiratory status. Chest 1995, 107:1253-9.
51. Hachida M, Hanayama N, Okamura T, Akasawa T, Maeda T, Bonkohara Y,
Endo M, Hashimoto A, Koyanagi H: The role of leukocyte depletion in
reducing injury to myocardium and lung during cardiopulmonary
bypass. ASAIO J 1995, 41:M291-M294.
52. Sheppard S, Gipps R, Smith D: Does leukocyte depletion during
cardiopulmonary bypass improve oxygenation indices in patients with
mild lung dysfunction?. Br J Anesth 2004, 93:789-92.
53. Warren O, Alexiou C, Massey R, Leff D, Purkayastha S, Kinross J, Darzi A,
Athanasiou T: The effects of various leukocyte filtration strategies in
cardiac surgery. Eur J Cardiothorac Surg 2007, 31:665-76.
54. Huang H, Yao T, Wang W, Zhu D, Zhang W, Chen H, Fu W: Continuous
ultrafiltration attenuates the pulmonary injury that follows open heart
surgery with cardiopulmonary bypass. Ann Thorac Surg 2003, 76:136-40.
55. Keenan HT, Thiagarajan R, Stephens KE, Williams G, Ramamoorthy C,
Lupinetti FM: Pulmonary function after modified venovenous
ultrafiltration in infants: a prospective, randomized trial. J Thorac
Cardiovasc Surg 2000, 119:501-5.
56. Pearl JM, Manning PB, McNamara JL, Saucier MM, Thomas DW: Effect of
modified ultrafiltration on plasma thromboxane B2, leukotriene B4, and
endothelin-1 in infants undergoing cardiopulmonary bypass. Ann Thorac
Surg 1999, 68:1369-75.
57. Mahmoud AB, Burhani MS, Hannef AA, Jamjoom AA, Al Githmi IS,
Baslaim GM: Effect of modified ultrafiltration on pulmonary function after
cardiopulmonary bypass. Chest 2005, 128:3447-53.
58. Nagashima M, Shin’oka T, Nollert G, Shum-Tim D, Rader CM, Mayer JE Jr:
High-volume continuous hemofiltration during cardiopulmonary bypass
attenuates pulmonary dysfunction in neonatal lambs after deep
hypothermic circulatory arrest. Circulation 1998, 98:II378-II384.
59. DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, Fillinger MP, Groom RC,
Forest RJ, Pieroni JW, Warren CS, Bogosian ME, Krumholz CF, Clark C,
Clough RA, Weldner PW, Lahey SJ, Leavitt BJ, Marrin CA, Charlesworth DC,
Marshall P, O’Connor GT: Lowest hematocrit on bypass and adverse
outcomes associated with coronary artery bypass grafting. Ann Thorac
Surg Northern New England Cardiovascular Disease Study Group 2001,
71:769-76.
60. Jansen P, te Velthuis H, Wildevuur W: Cardiopulmonary bypass with
modified fluid gelatine and heparin-coated circuits. Br J Anesth 1996,
6:13-9.
61. Takai H, Eishi K, Yamachika S, Hazama S, Nishi K, Ariyoshi T, Nakaji S,
Matsumaru I: The efficacy of low prime volume completely closed
cardiopulmonary bypass in coronary artery revascularization. Ann Thorac
Cardiovasc Surg 2004, 10:178-82.
62. Philippou H, Adami A, Davidson SJ, Pepper JR, Burman JF, Lane DA: Tissue
factor is rapidly elevated in plasma collected from the pericardial cavity
during cardiopulmonary bypass. Thromb Haemost 2000, 84:124-8.
63. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W:
Retransfusion of suctioned blood during cardiopulmonary bypass
impairs hemostasis. Ann Thorac Surg 1995, 59:901-7.
64. Schoenberger J, van Overen W, Bredee J: Systemic blood activation
during and after auto-transplantation. Ann Thorac Surg 1994, 57:1256-62.
65. Boonstra PW, van Imhoff GW, Eysman L, Kootstra GJ, Heide van der JN,
Karliczek GF, Wildevuur CR: Reduced platelet activation and improved
hemostasis after controlled cardiotomy suction during clinical
membrane oxygenator perfusions. J Thorac Cardiovasc Surg 1985, 89:900-
6.
66. Tatar H, Cicek S, Demirkilic U, Ozal E, Suer H, Ozturk O, Isiklar H: Topical use
of aprotinin in open heart operations. Ann Thorac Surg 1993, 55:659-61.
67. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W: Activation of
fibrinolysis in the pericardial cavity during cardiopulmonary bypass. J
Thorac Cardiovasc Surg 1993, 106:828-33.
68. Lodge AJ, Chai PJ, Daggett CW, Ungerleider RM, Jaggers J:
Methylprednisolone reduces the inflammatory response to
cardiopulmonary bypass in neonatal piglets: timing of dose is
important. J Thorac Cardiovasc Surg 1999, 117:515-22.
69. Wan S, LeClerc JL, Vincent JL: Inflammatory response to cardiopulmonary
bypass: mechanisms involved and possible therapeutic strategies. Chest
1997, 112:676-92.
70. Jansen NJ, van Oeveren W, van Vliet M, Stoutenbeek CP, Eysman L,
Wildevuur CR: The role of different types of corticosteroids on the
inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac
Surg 1991, 5:211-7.
71. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA: Aprotinin and
methylprednisolone equally blunt cardiopulmonary bypass-induced
inflammation in humans. J Thorac Cardiovasc Surg 1995, 110:1658-62.
72. Tassani P, Richter JA, Barankay A, Braun SL, Haehnel C, Spaeth P, Schad H,
Meisner H: Does high-dose methylprednisolone in aprotinin-treated
patients attenuate the systemic inflammatory response during coronary
artery bypass grafting procedures?. J Cardiothorac Vasc Anesth 1999,
13:165-72.
73. Chaney MA, Nikolov MP, Blakeman B, Bakhos M, Slogoff S: Pulmonary
effects of methylprednisolone in patients undergoing coronary artery
bypass grafting and early tracheal extubation. Anesth Analg 1998, 87:27-
33.
74. Chaney MA, Durazo-Arvizu RA, Nikolov MP, Blakeman BP, Bakhos M:
Methylprednisolone does not benefit patients undergoing coronary
artery bypass grafting and early tracheal extubation. J Thorac Cardiovasc
Surg 2001, 121:561-9.
75. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA: Aprotinin reduces
interleukin-8 production and lung neutrophil accumulation after
cardiopulmonary bypass. Anesth Analg 1996, 83:696-700.
76. Seghaye MC, Duchateau J, Grabitz RG, Jablonka K, Wenzl T, Marcus C,
Messmer BJ, von Bernuth G: Influence of low-dose aprotinin on the
inflammatory reaction due to cardiopulmonary bypass in children. Ann
Thorac Surg 1996, 61:1205-11.
77. Rahman A, Ustunda B, Burma O, Ozercan IH, Cekirdekci A, Bayar MK: Does
aprotinin reduce lung reperfusion damage after cardiopulmonary
bypass?. Eur J Cardiothorac Surg 2000, 18:583-8.
78. Prendergast TW, Furukawa S, Beyer AJ III, Eisen HJ, Mc Clurken JB,
Jeevanandam V: Defining the role of aprotinin in heart transplantation.
Ann Thorac Surg 1996, 62:670-4.
79. Upchurch GR, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H,
Ragno G, Francis S, Rodino LJ, Michelson AD, Loscalzo J: Effect of heparin
on fibrinolytic activity and platelet function in vivo. Am J Physiol 1996,
271:H528-H534.
80. John LC, Rees GM, Kovacs IB: Inhibition of platelet function by heparin.
An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg
1993, 105:816-22.
81. Videm V: Heparin in clinical doses ‘primes’ granulocytes to subsequent
activation as measured by myeloperoxidase release. Scand J Immunol
1996, 43:385-90.
82. Shastri KA, Logue GL, Stern MP, Rehman S, Raza S: Complement activation
by heparin-protamine complexes during cardiopulmonary bypass: effect
of C4A null allele. J Thorac Cardiovasc Surg 1997, 114:482-8.
83. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM: Reversal of heparin
anticoagulation by recombinant platelet factor 4 in humans. Circulation
1995, 91:2188-94.
84. Riess FC, Potzsch B, Behr I, Jager K, Rossing R, Bleese N, Schaper W, Muller-
Berghaus G: Recombinant hirudin as an anticoagulant during cardiac
operations: experiments in a pig model. Eur J Cardiothorac Surg 1997,
11:739-45.
85. Muller H, Hugel W, Reifschneider HJ, Horpacsy G, Hannekum A, Dalichau H:
Lysosomal enzyme activity influenced by various types of respiration
during extracorporeal circulation. Thorac Cardiovasc Surg 1989, 37:65-71.
Apostolakis et al. Journal of Cardiothoracic Surgery 2010, 5:1
http://www.cardiothoracicsurgery.org/content/5/1/1
Page 8 of 986. Magnusson L, Zemgulis V, Tenling A, Wernlund J, Tyden H, Thelin S,
Hedenstierna G: Use of a vital capacity maneuver to prevent atelectasis
after cardiopulmonary bypass: an experimental study. Anesthesiology
1998, 88:134-42.
87. Ishikawa S, Ohtaki A, Takahashi T, Sakata K, Koyano T, Kano M, Ohki S,
Kawashima O, Hamada Y, Morishita Y: PEEP therapy for patients with
pleurotomy during coronary artery bypass grafting. J Card Surg 2000,
15:175-8.
88. Berry CB, Butler PJ, Myles PS: Lung management during cardiopulmonary
bypass: is continuous positive airways pressure beneficial?. Br J Anaesth
1993, 71:864-8.
89. Stanley TH, Liu WS, Gentry S: Effects of ventilatory techniques during
cardiopulmonary bypass on post-bypass and postoperative pulmonary
compliance and shunt. Anesthesiology 1977, 46:391-5.
90. Friedman M, Sellke FW, Wang SY, Weintraub RM, Johnson RG: Parameters
of pulmonary injury after total or partial cardiopulmonary bypass.
Circulation 1994, 90:II262-II268.
91. Serraf A, Robotin M, Bonnet N, Detruit H, Baudet B, Mazmanian MG,
Herve P, Planche C: Alteration of the neonatal pulmonary physiology
after total cardiopulmonary bypass. J Thorac Cardiovasc Surg 1997,
114:1061-9.
92. John L, Ervine I: A study assessing the potential benefit of continued
ventilation during cardiopulmonary bypass. Interactive CardioVascular and
Thoracic Surgery 2008, 7:14-17.
93. Keavey PM, Hasan A, Au J, Dark JH: The use of 99Tcm-DTPA aerosol and
caesium iodide mini-scintillation detectors in the assessment of lung
injury during cardiopulmonary bypass surgery. Nucl Med Commun 1997,
18:38-43.
94. Davies MG, Hagen PO: Systemic inflammatory response syndrome. Br J
Surg 1997, 84:920-35.
95. Laffey J, Boylan J, Cheng D: The Systemic Inflammatory Response to
Cardiac Surgery. Anesthesiology 2002, 97:215-252.
96. Menasche P, Piwnica A: Free radicals and myocardial protection: a
surgical viewpoint. Ann Thorac Surg 1989, 47:939-45.
97. Seccombe JF, Pearson PJ, Schaff HV: Oxygen radical-mediated vascular
injury selectively inhibits receptor-dependent release of nitric oxide
from canine coronary arteries. J Thorac Cardiovasc Surg 1994, 107:505-9.
98. Haniuda M, Dresler CM, Mizuta T, Cooper JD, Patterson GA: Free radical-
mediated vascular injury in lungs preserved at moderate hypothermia.
Ann Thorac Surg 1995, 60:1376-81.
99. Lichtenstein SV, Ashe KA, el Dalati H, Cusimano RJ, Panos A, Slutsky AS:
Warm heart surgery. J Thorac Cardiovasc Surg 1991, 101:269-74.
100. Pyles LA, Fortney JE, Kudlak JJ, Gustafson RA, Einzig S: Plasma antioxidant
depletion after cardiopulmonary bypass in operations for congenital
heart disease. J Thorac Cardiovasc Surg 1995, 110:165-71.
101. Seccombe JF, Schaff HV: Coronary artery endothelial function after
myocardial ischemia and reperfusion. Ann Thorac Surg 1995, 60:778-88.
102. Kaneda T, Ku K, Inoue T, Onoe M, Oku H: Postischemic reperfusion injury
can be attenuated by oxygen tension control. Jpn Circ J 2001, 65:213-8.
103. Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, Gummert J,
Autschbach R, Mohr FW: Humoral immune response during coronary
artery bypass grafting: A comparison of limited approach, “off-pump”
technique, and conventional cardiopulmonary bypass. Circulation 2000,
102:III95-100.
104. Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP: Avoiding
cardiopulmonary bypass in multivessel CABG reduces cytokine response
and myocardial injury. Ann Thorac Surg 1999, 68:52-6.
105. Massoudy P, Zahler S, Tassani P, Becker BF, Richter JA, Pfauder M, Lange R,
Meisner H: Reduction of pro-inflammatory cytokine levels and cellular
adhesion in CABG procedures with separated pulmonary and systemic
extracorporeal circulation without an oxygenator. Eur J Cardiothorac Surg
2000, 17:729-36.
106. Massoudy P, Piotrowski JA, Wal van de HC, Giebler R, Marggraf G, Peters J,
Jakob HG: Perfusing and ventilating the patient’s lungs during bypass
ameliorates the increase in extravascular thermal volume after coronary
bypass grafting. Ann Thorac Surg 2003, 76:516-21.
107. Suzuki T, Fukuda T, Ito T, Inoue Y, Cho Y, Kashima I: Continuous pulmonary
perfusion during cardiopulmonary bypass prevents lung injury in
infants. Ann Thorac Surg 2000, 69:602-6.
108. Mendler N, Heimisch W, Schad H: Pulmonary function after biventricular
bypass for autologous lung oxygenation. Eur J Cardiothorac Surg 2000,
17:325-30.
109. Dobell AR, Bailey JS: Charles Drew and the origins of deep hypothermic
circulatoryarrest. Ann Thorac Surg 1997, 63:1193-9.
110. Richter JA, Meisner H, Tassani P, Barankay A, Dietrich W, Braun SL: Drew-
Anderson technique attenuates systemic inflammatory response
syndrome and improves respiratory function after coronary artery
bypass grafting. Ann Thorac Surg 2000, 69:77-83.
doi:10.1186/1749-8090-5-1
Cite this article as: Apostolakis et al.: Strategies to prevent
intraoperative lung injury during cardiopulmonary bypass. Journal of
Cardiothoracic Surgery 2010 5:1.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Apostolakis et al. Journal of Cardiothoracic Surgery 2010, 5:1
http://www.cardiothoracicsurgery.org/content/5/1/1
Page 9 of 9